



krebsforschung schweiz  
recherche suisse contre le cancer  
ricerca svizzera contro il cancro  
swiss cancer research

## CSSS: Conference on State of Science in Sarcoma 2022

Welcome to this **hybrid meeting** to be held on **Friday May 20<sup>th</sup>** starting at 13:00 AND **Saturday May 21<sup>st</sup>** starting at 09:00 CET

The Conference on State of Science in Sarcoma (CSSS) will be a **two-day hybrid conference**, in St Gallen, Switzerland. CSSS will address important areas of controversy regarding the diagnosis, treatment and follow-up of soft tissue sarcoma (STS).

The conference will include **short presentations and debates from international sarcoma experts** with a focus on the multidisciplinary management of STS and its challenges. An **interactive format** enables all participants to also vote on a set of controversial topics. Following the conference future scientific questions will be formulated, corresponding trials and registries proposed and action by stakeholders encouraged.

**Participants** from all medical disciplines with an **interest in sarcoma** are invited to join the CSSS. The conference will include short educational and debates from sarcoma experts who reviewed "Statements of Controversy" in STS. Results of a Delphi process and the votes on relevant questions will be presented and discussed.

**We look forward to your active participation.** You are welcome **to join the virtual meeting or specific parts of it.** Participation will be free of charge.

Please follow this link <https://www.medevent.ch/csss/2022> for further Information and Registration".

Venue

Zentraler Hörsaal, Haus 21, Kantonsspital St. Gallen

[https://www.kssg.ch/system/files/media\\_document/2022-04/Arealplan%20ohne%20Legende%20Englisch.pdf](https://www.kssg.ch/system/files/media_document/2022-04/Arealplan%20ohne%20Legende%20Englisch.pdf)

In case you would like to participate onsite, please contact Nicole Schenk [nicole.schenk@kssg.ch](mailto:nicole.schenk@kssg.ch)

*This program is supported by an Independent Educational Grant from Lotte & Adolf Hotz-Sprenger Stiftung, Bayer, Bristol Myers Squibb, Deciphera, Ipsen, Novartis, PharmaMar and Roche Pharma AG*